Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, entered into a license agreement with Pharmazz, Inc. (Pharmazz), a U.S. based biopharmaceutical company developing and commercialising drug products to treat critically ill patients, to commercialise the first-in-class innovative drug Centhaquine in India.
Developed by Pharmazz, centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by the Drugs Controller General of India (DCGI). As per the press release, Dr. Reddy’s has received exclusive rights to market and distribute centhaquine in India.
Pharmazz will be entitled to upfront payments and royalties. Dr. Reddy’s will market the product under the brand name Lyfaquin®, which it shall own. In addition to India, Dr. Reddy’s also receives marketing rights for Lyfaquin® from Pharmazz for Nepal.
M.V. Ramana, Chief Executive Officer, Branded Markets (India and emerging markets), Dr. Reddy’s said, “The partnership with Pharmazz and launch of this first-in-class drug marks the latest in our effort to enter into strategic collaborations to bring novel molecules to India to meet genuine unmet patient needs. The clinical studies for Lyfaquin® have demonstrated significantly better and promising outcomes, making it as a potential add-on drug in the management of hypovolemic shock and enhancing the current standard of care for its treatment in India”.
Dr. Prof. Anil Gulati, Inventor, CEO, and Chairman of the Board of Directors of Pharmazz added, “India’s emergence as a hub for developing and introducing innovative medicines is a remarkable achievement. It reflects the country’s growing capabilities in research and development within the pharmaceutical sector. It is a large step for Pharmazz to partner with Dr. Reddy’s, a leading global pharmaceutical company from India. For patients with hypovolemic shock, I believe Dr. Reddy’s is the best partner for Pharmazz to market Centhaquine, an innovative, first-in-class novel resuscitative agent, in India”.
